Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.

European urology - 1 Jan 1998

Kelly W K

Abstract excerpt

Therapeutic options for patients with metastatic prostate cancer relapsing from primary hormonal therapy are limited. On the selective discontinuation of flutamide in patients that have relapsed on combined androgen ablation, a third of the patients will show a significant clinical benefit for 4-...

Topics

Androgen Antagonists
Androgen Receptor Antagonists
Antineoplastic Agents, Hormonal
Flutamide
Humans
Male
Mutation
Prognosis
Prostatic Neoplasms
Receptors, Androgen
Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9854191
DOI: 10.1159/000052292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9854191-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.PMID 9854191Read ↗

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Semantic proximity Read ↗

The antiandrogen withdrawal syndrome.Semantic proximity Read ↗

Molecular basis for the antiandrogen withdrawal syndromeSemantic proximity Read ↗

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.Semantic proximity Read ↗

[Antiandrogen withdrawal syndrome].Semantic proximity Read ↗

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.Semantic proximity Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.Semantic proximity Read ↗

Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: a Viable Alternative to First Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment to Achieve Early PSA ResponseSemantic proximity Read ↗

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read ↗

A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.Semantic proximity Read ↗

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.